ecancermedicalscience

Case Report

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib

30 May 2022
Shubham Tomar, Lakhan Kashyap, Akhil Kapoor

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant syndrome associated with fumarate hydratase (FH) gene mutation leading to defective DNA double-strand break repair mechanism. Although these tumours have an aggressive presentation, they respond well to targeted therapy with fewer adverse effects. Here we present a case of a 42-year-old female having isolated renal cell carcinoma, papillary type 2, carrying a mutation in the FH gene without cutaneous and uterine involvement. Her tumour responded well to erlotinib and bevacizumab combination and she was on treatment for 23 months. This report adds to the current literature and can help to define treatment protocols for HLRCC.

Related Articles

Mudathir Mohamed Bafadni, Yassin Mohammed Osman, Mohammed El Imam Mohammed Ahmed, Mussab Mahjoub Taha, Dafulla Abu Idris, Khalid Eltahir Khalid Kheiralla, Moawia Mohammed Ali Elhassan, Mohamed Daffalla Awadalla Gismalla, Sami Mahjoub Taha Awad
Arnav Tongaonkar, Vijai Simha, Nandini Menon, Vanita Noronha, Ganesh Bakshi, Vedang Murthy, Santosh Menon, Nilesh Sable, Rahul Krishnatry, Palak Popat, Mahendra Pal, Gagan Prakash, Archi Agarwal, Bhagyashri Shivaji Jadhav, Kumar Prabhash, Amit Joshi
Hassan Abdelilah Tafenzi, Farah Choulli, Anass Baladi, Ismail Essaadi, Rhizlane Belbaraka
Brandon A Niyibizi, Eulade Muhizi, Daniella Rangira, Diana A Ndoli, Innocent M Nzeyimana, Jackson Muvunyi, Magnifique Irakoze, Madeleine Kazindu, Alex Rugamba, Khadidja Uwimana, Yuanzhen Cao, Eulade Rugengamanzi, Jean de Dieu Kwizera, Achille VC Manirakiza, Fidel Rubagumya
Melinda Mushonga, Omar Abdihamid, Christian Ntizimira, Gad Murenzi, Sidy Ka, Nazik Hammad, Fidel Rubagumya
Malar Velli Segarmurthy, Richard Boon-Leong Lim, Salimah Othman, Sri Wahyu Taher, Harenthri Devy, Nirmala Bhoo-Pathy